← FDA DRUG APPROVALS
FDA ANDA · ANDA220042
DEFLAZACORT ORAL SUSPENSION
deflazacort
Sponsor: ZYDUS LIFESCIENCES
APPLICATION
ANDA220042
TYPE
ANDA
ORIGINAL APPROVAL
2025-10-03
LATEST ACTION
2026-01-13
ROUTE
ORAL
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription
Products
DEFLAZACORTPrescription
DEFLAZACORT 22.75MG/ML · SUSPENSION · ORAL
Approval history
2026-01-13Labeling · Supplement 1 · standardAP
2025-10-03UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.